Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS

Despite extensive efforts, oncogenic KRAS remains resistant to targeted therapy. Combined downstream RAL-TBK1 and MEK inhibition induces only transient lung tumor shrinkage in KRAS-driven genetically engineered mouse models (GEMMs). Using the sensitive KRAS;LKB1 (KL) mutant background, we identify Y...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Cell
Asıl Yazarlar: Kitajima, Shunsuke, Asahina, Hajime, Chen, Ting, Guo, Sujuan, Quiceno, Laura Gutierrez, Cavanaugh, Jillian D., Merlino, Ashley A., Tange, Shoichiro, Terai, Hideki, Kim, Jong Wook, Wang, Xiaoen, Zhou, Shan, Xu, Man, Wang, Stephen, Zhu, Zehua, Thai, Tran C., Takahashi, Chiaki, Wang, Yujin, Neve, Richard, Stinson, Susanna, Tamayo, Pablo, Watanabe, Hideo, Kirschmeier, Paul T., Wong, Kwok-Kin, Barbie, David A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6422029/
https://ncbi.nlm.nih.gov/pubmed/30205046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.08.009
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller